The Prognostic Significance of Receptor Status in Patients with Early Breast Cancer
The aim of the investigation is to study prognostic value of tumor receptor status in early breast cancer (I stage).
Materials and Methods. There was performed retrospective analysis of case histories of 1036 patients with early breast cancer (T1N0M0-stage), who were treated in N.N. Blokhin Russian Cancer Research Center and the Clinic of Russian Medical Academy for Postgraduate Education from 1985 till 2009. There was studied the prognostic significance of estrogen receptor (ER), progesterone receptor (PR) and HER2, as well as prognostic value of HER2 hyperexpression in early breast cancer both in independent form, and in combination with the receptors of steroid hormones.
Results. Based on the combination of receptors there were distinguished immunohistochemical subtypes of breast cancer: luminal A and B, triple-negative cancer and cancer with HER2 overexpressoin. The presence or absence of receptors of steroid hormones ER and PR was stated to have no independent prognostic significance in early breast cancer. HER2 hyperexpression shows no prognostic value in the analysis of overall survival, but it is an unfavourable factor for recurrence free survival both as an independent form, and in combination with the steroid hormone receptors.
- Alan S. Coates, Marco Colleoni, Aron Goldhirsch. Is adjuvant chemotherapy useful for women with luminal a breast cancer? Journal of Clinical Oncology 2012; 30: 1–4.
- Islam T., Matsuo K., Ito H., Hosono S., Watanabe M., Iwata H., Tajima K., Tanaka H. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negativebreast cancer in Japanese women. Ann Oncol 2012 Sept; 23(9): 2435–2441.
- Kwon M.J., Park S., Choi J.Y., Oh E., Kim Y.J., Park Y.H., Cho E.Y., Kwon M.J., Nam S.J., Im Y.H., Shin Y.K., Choi Y.L. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 2012 Feb 28; 106(5): 923–930.
- Xie W., Yang J., Cao Y., Peng C., Ning H., Zhang F., You J. Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer. Tumour Biol 2012 Feb; 33(1): 63–71.
- Oliveira-Costa J.P., Zanetti J.S., Silveira G.G., Soave D.F., Oliveira L.R., Zorgetto V.A., Soares F.A., Zucoloto S., Ribeiro-Silva A. Differential expression of HIF-1a in CD44+CD24-/low breast ductal carcinomas. Diagn Pathol 2011 Aug 8; 6: 73.
- Kim S.R., Paik S. Genomics of adjuvant therapy for breast cancer. Cancer J 2011 Nov–Dec; 17(6): 500–504.
- Lu M., Li B., Li Y., Mao X., Yao F., Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancerpatients in northeast china. Asian Pac J Cancer Prev 2011; 12(9): 2411–2417.
- Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009 May 20; 101(10): 736–750.
- Pazaiti A., Fentiman I.S. Basal phenotype breast cancer: implications for treatment and prognosis. Womens Health (Lond Engl) 2011 Mar; 7(2): 181–202.
- Tran B., Bedard P.L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011 Nov 30; 13(6): 221.
- Arnes J.B., Bégin L.R., Stefansson I., Brunet J.S., Nielsen T.O., Foulkes W.D., Akslen L.A. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol 2009 Feb; 62(2): 139–144.
- Gucalp A., Traina T.A. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011; р. 696208.
- Collins L.C., Martyniak A., Kandel M.J., Stadler Z.K., Masciari S., Miron A., Richardson A.L., Schnitt S.J., Garber J.E. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009 Jul; 33(7): 1093–1097.
